Emerging Frontiers in SCLC: First-Line Maintenance, Second-Line Strategies, and Novel Targeted Approaches
This symposium will review current and emerging treatment strategies for small cell lung cancer (SCLC), with a focus on therapeutic decision-making across the disease continuum. Faculty will discuss current standards of care, including the role of immunotherapy-based first-line treatment, evolving treatment continuation and maintenance approaches, and persistent unmet needs in SCLC. The program will also examine evidence supporting current second-line treatment options, including patient selection and treatment sequencing following prior immunotherapy exposure, as well as clinical considerations that influence management in routine practice. In addition, the symposium will review emerging therapeutic approaches under clinical investigation, including DLL3-directed therapies, bispecific antibodies, antibody-drug conjugates, and other novel immunotherapy-based and targeted strategies. Faculty will discuss the available clinical evidence and the potential role of these approaches in first-line and recurrent disease settings. Through expert presentations and case-based discussion, attendees will explore the application of current and emerging evidence to treatment planning, toxicity management, and individualized care for patients with newly diagnosed and recurrent SCLC.
Session recordings and presentation slides will be posted on this page as soon as they become available. Please check back soon for updates.
Program at a Glance
Dr. Jacob Sands is a thoracic medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School. At this WCLC, he presented the update on Tropion Lung01 of Datopotamab deruxtecan vs docetaxel for non-small cell lung cancer as well as the update on Tarlatamab for small cell lung cancer Is a co-founder and President of the Rescue Lung Society, a non-profit medical society focused on lung screening.
Dr. Tanizaki is a medical oncologist who specializes thoracic oncology and molecular targeted therapy in Japan. She received MD in 2007 and PhD in 2011 at Kindai University, faculty of medicine, Japan. After having trained as postdoctoral fellow at Dana-Farber Cancer Institute, Dr, Pasi Janne’s lab, from 2012 to 2015, she is back in Japan and working as a medical oncologist at Kindai University, faculty of medicine.
Stages of academic/professional career 08/2022 Appointment W2 Professor for Experimental Tumorherapy, TU Dresden 01/2021 Habiliation/Venia Legendi, TU Dresden Since 01/2019 Director NCT Clinical Trial-Center, Dresden 05/2015 Board certification Hematology/Oncology Since 03/2013 Director NCT/UCC Early Clinical Trial Unit 02/2013 Board Certification Internal Medicine 2010-2011 Gerok Rotation to Max-Planck Institute for Molecular and Cellular Biology, Dresden, Prof. Dr. Frank Buchholz 2005-2013 Resident, University Hospital C.-G.-Carus Dresden
Dr. Han graduated in 1989 from the College of Medicine, the Catholic University of Korea, Seoul, Korea, and obtained her MS and PhD degrees in internal medicine in 1995 and 1998, respectively. She joined the National Cancer Center in 2001 and directed the Center for Lung Cancer from 2010 to 2017 and the Division of Precision Medicine from 2016 to Mar. 2019. In 2003-2004, she joined the University of Texas MD Anderson Cancer Center in Texas, USA, as a visiting assistant professor. In 2016-2017, she was elected to the Presidential Advisory Council on Science & Technology and contributed to the National Precision Medicine Project. Dr. Han led the precision medicine project for lung cancer at the National Cancer Center and co-leads the proteogenomic project of never-smoking lung cancer with the Korean Institute of Science and Technology (KIST) and Korean Research Institute of Bioscience and Biotechnology (KRIBB) from 2017-2021. She is now working as a professor and a principal scientist at the National Cancer Center, Korea.
Dr. Jacob Sands is a thoracic medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School. At this WCLC, he presented the update on Tropion Lung01 of Datopotamab deruxtecan vs docetaxel for non-small cell lung cancer as well as the update on Tarlatamab for small cell lung cancer Is a co-founder and President of the Rescue Lung Society, a non-profit medical society focused on lung screening.